A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Watson Pharmaceuticals
• Treatments: Mandelic Acids; Oxybutynin

Criteria

Inclusion Criteria:

• Females and males, 18 years of older with overactive bladder symptoms

Exclusion Criteria:

• Treatable conditions that may cause urinary incontinence

• Medical conditions in which it would be unsafe to use an anti-cholinergic agent.

• The use of concomitant drugs that would confound the efficacy evaluation.

• The use of concomitant drugs that would be unsafe with an anti-cholinergic agent.